LIFDOTCPharmaceutical PreparationsFiscal year ends December 31
LFTD PARTNERS INC.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 14, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.48M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
34.2%−2.1 pts over 5 years
Operating margin
2.5%+30.9 pts over 5 years
Net margin
-67.3%−38.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.1% | -13.7% | +47.2% | – | |
| Gross profit | -1.1% | -15.6% | +45.5% | – | |
| Operating income | – | -54.7% | – | – | |
| Free cash flow | – | -17.3% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 317.0% | -11.0% | -99.2% | |
| Return on assets | -680.8% | -8.9% | -74.3% | |
| Current ratio | 0.00 | 1.41 | 3.04 | |
| Interest coverage | – | -23.3× | – | |
| Inventory turnover | – | 10.6× | 2.4× | |
| Capex to revenue | – | 1.3% | 0.3% | |
| Diluted shares | 2M | 6M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lftd Partners generated $11.58M from operations and spent $2.95M on capital expenditure, dividends and share buybacks. 85% of that went back into the business.
Generated
$11.58M
Used
$2.95M
Capital expenditure$2.51M85%Dividends$11.84K0%Share buybacks$424.44K14%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-67.3%
×Asset turnover1.10×
×Equity multiplier1.33×
=Return on equity, FY2025-99.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -67.3% | 1.10× | 1.33× | -99.2% |
| FY2024 | -5.0% | 0.75× | 1.30× | -4.9% |
| FY2023 | 4.2% | 1.12× | 1.26× | 5.9% |
| FY2022 | 12.5% | 1.43× | 1.30× | 23.2% |
| FY2021 | 18.3% | 0.94× | 1.37× | 23.6% |
| FY2020 | -28.7% | 0.31× | 1.23× | -11.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$24.86M
- Cash generatingOperating cash flow above zero$1.32M
- Return on assets improvedROA up on the prior year-3.6% → -52.2%
- Earnings backed by cashOperating cash flow above net income$1.32M vs -$24.86M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.70 → 3.04
- No dilutionShare count did not rise15M → 15M
- Gross margin improvedGross margin up on the prior year34.17% → 34.18%
- More efficientAsset turnover rose0.73 → 0.78